Chronic Mucocutaneous Candidiasis (CMC) Cell Models for Research

Chronic Mucocutaneous Candidiasis (CMC) is a primary immunodeficiency characterized by persistent or recurrent infections of the skin, nails, and mucous membranes with Candida species, primarily Candida albicans. The exact global prevalence is unknown, but it is considered rare, with estimates ranging from 1 in 100,000 to 1 in 500,000 individuals (WHO, 2023). CMC can be inherited (autosomal dominant or recessive) or acquired, often associated with autoimmune polyendocrine syndrome type 1 (APS-1) or thymoma. The clinical impact is significant: patients suffer from chronic discomfort, disfigurement, and risk of invasive candidiasis. The 5-year survival is generally good if managed, but complications such as esophageal strictures and squamous cell carcinoma can arise (NCI, 2023). Key risk factors include mutations in genes involved in Th17 cell differentiation and IL-17 signaling, such as STAT1, STAT3, IL17RA, IL17F, ACT1, and CARD9.

CMC serves as an excellent model for studying antifungal immunity, particularly the role of Th17 cells and IL-17 signaling in mucosal defense. The disease has well-defined genetic subtypes, making it ideal for genotype-phenotype correlation studies. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and ClinVar, provide comprehensive mutation data. Open questions include the precise molecular mechanisms of IL-17 resistance, the role of STAT1 gain-of-function mutations, and the development of targeted therapies. Gene-edited cell models are crucial for dissecting these pathways and testing novel immunomodulatory agents.

CMC is not a cancer, but it predisposes to certain cancers, particularly squamous cell carcinoma of the oral cavity. The major pathways involved in CMC pathogenesis are:

1. Th17 Cell Differentiation Pathway: IL-6, TGF-β, IL-21, and IL-23 drive Th17 differentiation. Mutations in STAT3 (loss-of-function) impair Th17 development, leading to CMC.

2. IL-17 Signaling Pathway: IL-17A and IL-17F bind to IL-17RA/RC heterodimer, activating NF-κB and MAPK pathways. Mutations in IL17RA, IL17F, or ACT1 disrupt this signaling.

3. STAT1 Signaling Pathway: Gain-of-function mutations in STAT1 lead to enhanced STAT1 phosphorylation and nuclear localization, which suppresses Th17 differentiation and promotes Th1 responses. This is the most common cause of autosomal dominant CMC.

4. CARD9 Pathway: CARD9 is an adaptor protein in the C-type lectin receptor pathway, essential for antifungal immunity. Mutations impair cytokine production, including IL-17.

Data from TCGA (not applicable), COSMIC (not applicable), and ClinVar (2023).

The key signaling networks deregulated in CMC include:

• • IL-17 Signaling Network: IL-17A/F → IL-17RA/RC → ACT1 → TRAF6 → NF-κB and MAPK. Mutations in any component disrupt the network.
• • JAK-STAT Signaling: Cytokines (IFN-γ, IL-6, IL-21) activate JAKs, which phosphorylate STATs. Gain-of-function STAT1 enhances STAT1 activity, leading to overexpression of STAT1 target genes and suppression of Th17.
• • C-Type Lectin Receptor Pathway: Dectin-1/2 → Syk → CARD9 → BCL10-MALT1 → NF-κB. CARD9 mutations impair this pathway, reducing IL-17 and other cytokines.
• • Th17 Differentiation Network: TGF-β, IL-6, IL-21, IL-23 → STAT3, RORγt. Loss-of-function STAT3 impairs this network.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) or primary epithelial cells can recapitulate mucosal immunity. Advantages include 3D architecture, cell-cell interactions, and the ability to model Candida infection. However, they are more complex and less scalable than cell lines.

Animal models for CMC include:

• • Genetically Engineered Mouse Models (GEMM): Mice with conditional knockouts of IL17RA, STAT3, or CARD9 in specific tissues. For example, IL17RA knockout mice are susceptible to oropharyngeal candidiasis.
• • Induced Models: Immunosuppressed mice (e.g., corticosteroid-treated) infected with Candida albicans to mimic CMC.
• • Patient-Derived Xenografts (PDX): Not commonly used for CMC, but can be used to study associated cancers.
• • Humanized Mice: Mice engrafted with human immune cells to study human-specific mutations.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific mutations found in CMC patients. For example:

• • STAT1 Gain-of-Function Knock-In Cell Lines: Introduce a point mutation (e.g., R274Q) into STAT1 to mimic autosomal dominant CMC.
• • STAT3 Loss-of-Function Knockout Cell Lines: Disrupt STAT3 to model autosomal dominant hyper-IgE syndrome (HIES) with CMC.
• • IL17RA Knockout Cell Lines: Knock out IL17RA to study defective IL-17 signaling.
• • CARD9 Knockout Cell Lines: Knock out CARD9 to model impaired antifungal immunity.

These gene-edited cell lines are commercially available and sequence-verified, providing researchers with reliable tools to study disease mechanisms and test therapeutic interventions. They accelerate research by eliminating the need for primary patient cells, which are limited and difficult to expand.

Gene-edited cell lines are used to validate the functional consequences of CMC-associated mutations. For example:

• • STAT1 Gain-of-Function: Knock-in cell lines show enhanced STAT1 phosphorylation and nuclear localization, leading to increased expression of STAT1 target genes and suppression of Th17 differentiation.
• • STAT3 Loss-of-Function: Knockout cell lines exhibit impaired Th17 differentiation and reduced IL-17 production.
• • IL17RA Knockout: Cells show defective IL-17 signaling, as measured by reduced NF-κB activation and cytokine production.

These models allow researchers to dissect the molecular pathways and identify potential therapeutic targets.

Isogenic cell line pairs (wild-type vs. mutant) are powerful tools for drug screening. For example:

• • Antifungal Drug Screening: Test the efficacy of antifungal agents (e.g., fluconazole, caspofungin) in IL17RA knockout cells to assess the role of IL-17 signaling in antifungal defense.
• • Immunomodulatory Drug Testing: Evaluate drugs that modulate STAT1 signaling (e.g., JAK inhibitors) in STAT1 gain-of-function cells.
• • Resistance Modeling: Generate cells with acquired resistance to antifungal drugs by chronic exposure, then use CRISPR to identify resistance mechanisms.

CRISPR screens using gene-edited cell lines can identify synthetic lethal interactions and biomarkers. For example:

• • Synthetic Lethality Screens: In STAT1 gain-of-function cells, screen for genes whose knockdown selectively kills these cells, revealing potential therapeutic targets.
• • Biomarker Identification: Compare gene expression profiles of wild-type and mutant cells to identify biomarkers of disease severity or treatment response.
• • Functional Genomics: Use CRISPR knockout libraries to identify genes that modulate IL-17 signaling or antifungal immunity.